Summit Therapeutics's top three insider shareholders as of June 09, 2026 are Mahkam Zanganeh (Co Chief Executive Officer, 595.88Mn shares), Robert W Duggan (Co Chief Executive Officer, 595.88Mn shares), Mahkam Zanganeh (Co Ceo President, 34.46Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Robert W Duggan | Co Chief Executive Officer | 570,073,879 | 25,801,154 | 23 Oct, 2025 |
| Jeff Huber | - | 0 | 44,052 | 13 Sep, 2024 |
| Mahkam Zanganeh | Co Chief Executive Officer | 0 | 595,875,033 | 23 Oct, 2025 |
| Manmeet Singh Soni | Coo And Cfo | 3,073,603 | 0 | 23 Oct, 2025 |
| Ankur Dhingra | Chief Financial Officer | 0 | 354,958 | 27 Mar, 2024 |
| Bhaskar Anand | Chief Accounting Officer | 159,751 | 0 | 23 Oct, 2025 |
| Yu Xia | - | 0 | 32,057,147 | 23 Oct, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 08 Jan, 2026 | Bhaskar Anand | Stock Option (right to buy) | A | 30,000 | - | 30,000 | D | A |
| 02 Jan, 2026 | Yu Xia | Stock Option (right to buy) | A | 35,000 | - | 35,000 | D | A |
| 02 Jan, 2026 | Kenneth A Clark | Stock Option (right to buy) | A | 35,000 | - | 35,000 | D | A |
| 02 Jan, 2026 | Jeff Huber | Stock Option (right to buy) | A | 35,000 | - | 35,000 | D | A |
| 02 Jan, 2026 | Yu Xia | Stock Option (right to buy) | A | 35,000 | - | 35,000 | D | A |
| 02 Jan, 2026 | Mahkam Zanganeh | Stock Option (right to buy) | A | 11,232 | $8.76 | 11,232 | I | A |
| 02 Jan, 2026 | Robert W Duggan | Stock Option (right to buy) | A | 11,232 | $8.76 | 11,232 | D | A |
| 02 Jan, 2026 | Mahkam Zanganeh | Stock Option (right to buy) | A | 11,232 | $8.76 | 11,232 | I | A |
| 02 Jan, 2026 | Robert F. Booth | Stock Option (right to buy) | A | 35,000 | - | 35,000 | D | A |
| 02 Jan, 2026 | Mostafa Ronaghi | Stock Option (right to buy) | A | 35,000 | - | 35,000 | D | A |
| 02 Jan, 2026 | Alessandra Cesano | Stock Option (right to buy) | A | 35,000 | - | 35,000 | D | A |
| 02 Jan, 2026 | Alessandra Cesano | Stock Option (right to buy) | A | 3,219 | $8.76 | 3,219 | D | A |
| 02 Jan, 2026 | Jeff Huber | Stock Option (right to buy) | A | 9,885 | $8.76 | 9,885 | D | A |
| 02 Jan, 2026 | Kenneth A Clark | Stock Option (right to buy) | A | 17,796 | $8.76 | 17,796 | D | A |
| 02 Jan, 2026 | Robert F. Booth | Stock Option (right to buy) | A | 7,180 | $8.76 | 7,180 | D | A |
| 21 Oct, 2025 | Bhaskar Anand | Common Stock | A | 26,680 | $18.74 | 159,751 | D | A |
| 21 Oct, 2025 | Mahkam Zanganeh | Common Stock | A | 266,808 | $18.74 | 25,724,474 | I | A |
| 21 Oct, 2025 | Mahkam Zanganeh | Common Stock | A | 266,808 | $18.74 | 25,724,474 | I | A |
| 21 Oct, 2025 | Robert W Duggan | Common Stock | A | 13,980,789 | $18.74 | 570,073,879 | D | A |
| 21 Oct, 2025 | Yu Xia | Common Stock | A | 533,617 | $18.74 | 32,057,147 | I | P |